首页> 外文期刊>Journal of Patient-Reported Outcomes >A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
【24h】

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

机译:针对罕见疾病临床试验的务实的患者报告结局策略:EORTC项目库在骨髓增生异常综合症,慢性粒细胞单核细胞白血病和急性髓细胞性白血病中的应用

获取原文
           

摘要

Abstract BackgroundNovel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). The objective of the current study was to select supplemental items to add to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) to ensure content coverage of all important clinical concepts in patients with higher-risk (HR) MDS, low-blast count?(LB) AML, and CMML, thus, improving the instrument’s ability to detect clinically meaningful treatment benefit for this context of use.MethodsOur mixed methods approach comprised literature review, clinician consultation ( n =?3), and qualitative and quantitative analysis of two stages of patient interview data ( n =?14, n =?18) to select library bank items to supplement a generic cancer PRO, the EORTC QLQ-C30.ResultsUnique symptom ( n =?54) and impact ( n =?72) concepts were organized into conceptual frameworks of treatment benefit, compared with EORTC QLQ-C30 items and conceptual gaps identified. Supplemental items ( n =?13) addressing those gaps were selected from the EORTC Item Library and tested with patients. Supplemental item endorsement frequencies met World Health Organization Quality of Life criteria, suggesting good targeting and relevance for this sample. However, three supplemental items were confirmed as problematic based upon cognitive debriefing results, and expert clinical consultations. Ultimately, 10 supplemental items ( n =?7 symptom; n =?3 impact) were selected for the MDS/AML/CMML context.ConclusionSupplemental items were selected to enhance the conceptual coverage of the EORTC QLQ-C30 in the areas of fatigue, shortness of breath, and functioning.
机译:摘要背景需要新颖,务实,以患者为中心的策略,以确保在针对诸如增生异常综合症(MDS),急性髓性白血病(AML)和慢性病等罕见疾病的临床试验研究中确保适合患者使用的患者报告结果(PRO)仪器骨髓单核细胞白血病(CMML)。当前研究的目的是选择补充项目,以添加到欧洲癌症研究和治疗组织(EORTC)生命质量核心30(QLQ-C30)中,以确保更高的患者涵盖所有重要临床概念的内容风险(HR)MDS,低爆炸计数(LB)AML和CMML,从而提高了该仪器在这种使用背景下检测具有临床意义的治疗益处的能力。方法我们的混合方法包括文献回顾,临床医生咨询(n =?3),并对两个阶段的患者访谈数据(n =?14,n =?18)进行定性和定量分析,以选择库库项目以补充通用癌症PRO EORTC QLQ-C30。与EORTC QLQ-C30的项目和确定的概念差距进行比较,将概念[= 54]和影响(n =?72)的概念组织到治疗收益的概念框架中。从EORTC项目库中选择了弥补这些差距的补充项目(n =?13),并与患者进行了测试。补充项目认可的频率符合世界卫生组织的生活质量标准,表明该样本具有良好的针对性和相关性。但是,根据认知汇报的结果和专家的临床咨询,确认了三个补充项目存在问题。最终,为MDS / AML / CMML环境选择了10个补充项目(n =?7症状; n =?3影响)。结论选择了补充项目以增强EORTC QLQ-C30在疲劳领域的概念覆盖率,呼吸急促,功能正常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号